Physician- and Patient-based Barriers to NGS Testing

Recruiting now · Not applicable

Conditions studied: Metastatic Prostate Cancer

In brief

The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.

Key facts

Study ID

NCT07209176

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

256

Starts

2026-01-06

Expected to finish

2027-09-06

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• men diagnosed with metastatic prostate cancer
• seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026

You may not qualify if…

• Patients who have already had NGS testing performed.

Where it is running

• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.